Exelixis Clinical Trials
Exelixis is currently enrolling patients in our two cabozantinib phase 3 prostate cancer trials, COMET-1 and COMET-2. We are also continuing to follow patients enrolled in our phase 2 Randomized Discontinuation Trial (RDT), which is evaluating cabozantinib in a variety of cancer indications, and in a phase 1B study that is evaluating potential interactions between cabozantinib and other drugs in patients with renal cell carcinoma or differentiated thyroid cancer.
| Status | Tumor Types Covered | Trial Description | Phase | Trial Information1 |
|---|---|---|---|---|
| Recruiting | Castration-Resistant Prostate Cancer | Efficacy of cabozantinib (XL184) versus prednisone in castration-resistant prostate cancer (COMET-1): evaluation of overall survival. |
Phase 3 | NCT01605227 |
| Recruiting | Castration-Resistant Prostate Cancer | Efficacy of cabozantinib (XL184) versus mitoxantrone plus prednisone in castration-resistant prostate cancer (COMET-2): evaluation of pain response. | Phase 3 | NCT01522443 |
| Approved for marketing | Medullary Thyroid Cancer | Expanded Access Study of Cabozantinib (XL184) in Medullary Thyroid Cancer | Expanded Access | NCT01683110 |
| Active, enrollment completed | Medullary Thyroid Cancer | Efficacy of cabozantinib (XL184) in Advanced Medullary Thyroid Cancer (EXAM) | Phase 3 | NCT00704730 |
| Active, enrollment completed | Breast Cancer Gastric/GE Junctional Cancer Hepatocellular Carcinoma Melanoma Castration-Resistant Prostate Cancer Non-small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Small Cell Lung Cancer |
Randomized Discontinuation Trial (RDT) Study of cabozantinib in Adults With Advanced Malignancies |
Phase 2 | NCT00940225 |
| Active, enrollment completed | Differentiated Thyroid Cancer Renal Cell Carcinoma |
Drug-Drug Interaction Safety Study | Phase 1B | NCT01100619 |
For more information on the Phase 3 COMET clinical trials in Castration Resistant Prostate Cancer please visit CometClinicalTrials.com.
For a detailed list of cabozantinib clinical studies posted on ClinicalTrials.gov please click HERE. For further information regarding all clinical trials please contact Exelixis Medical Information at 1-888-EXELIXIS (1-888-393-5494) or at druginfo@exelixis.com.
References:
- U.S. National Institutes of Health, ClinicalTrials.gov Web site: http://www.clinicaltrials.gov/